Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

While employers typically cover the medications for diabetes, fewer of them do so for weight loss, in part because of the ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...